Knight Therapeutics Inc.
GUD.TO
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.95% | 2.39% | 4.42% | 7.97% | 17.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.95% | 2.39% | 4.42% | 7.97% | 17.73% |
| Cost of Revenue | -0.86% | -4.65% | 5.67% | 9.16% | 21.46% |
| Gross Profit | 7.38% | 11.16% | 3.01% | 6.63% | 13.68% |
| SG&A Expenses | 2.96% | -1.06% | -4.92% | -8.73% | -1.61% |
| Depreciation & Amortization | -12.91% | -13.83% | -14.78% | -15.70% | -6.49% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.86% | -4.07% | -0.18% | 0.20% | 9.52% |
| Operating Income | 484.56% | 157.35% | 130.20% | 136.92% | 88.88% |
| Income Before Tax | -69.34% | 12.69% | 9.31% | 51.99% | 50.17% |
| Income Tax Expenses | 88.65% | 78.00% | 42.19% | 64.21% | 13.82% |
| Earnings from Continuing Operations | -305.02% | -34.85% | -16.72% | 46.29% | 69.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -305.02% | -34.85% | -16.72% | 46.29% | 69.41% |
| EBIT | 484.56% | 157.35% | 130.20% | 136.92% | 88.88% |
| EBITDA | 9.58% | 29.21% | 4.68% | 24.24% | 35.42% |
| EPS Basic | -421.67% | -54.56% | -33.69% | 39.12% | 72.69% |
| Normalized Basic EPS | -361.25% | -6,925.00% | -751.35% | 82.39% | 116.46% |
| EPS Diluted | -388.40% | -49.10% | -26.96% | 36.85% | 71.11% |
| Normalized Diluted EPS | -361.25% | -6,925.00% | -751.35% | 82.39% | 116.46% |
| Average Basic Shares Outstanding | -8.06% | -8.60% | -8.36% | -7.25% | -5.09% |
| Average Diluted Shares Outstanding | -8.16% | -8.61% | -8.30% | -7.19% | -5.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
